PSMA- Theranostics

Prostate cancer is the second most common malignancy worldwide. Social cognitive awareness and early diagnosis have led to primary treatments with curative intent, including radical prostatectomy (RP) or external beam radiotherapy (EBRT). Both treatments are effective and have contributed to a 97.5% five-year survival rate. Unfortunately, nearly 1/3 of these patients experience biochemical recurrence, characterized by an increase in serum PSA. The recently introduced PSMA-Theranostics will be used not only for more specific imaging of residual tumor cells, but also to guide more personalized salvage therapy.